Yasmin M. Syam

Yasmin M. Syam

Auto-generated profile, based on publicly available information

Yasmin M. Syam

Department of Therapeutic Chemistry, National Research Centre, P.B. Box 12262, El-Bohouth St., Cairo, Egypt

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 May 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SESomaia Abd El-Karim
Somaia Abd El-Karim
YSYasmin M. Syam
Yasmin M. Syam
AKAhmed M. El Kerdawy
Ahmed M. El Kerdawy
TATamer M. Abdelghany
Tamer M. Abdelghany

1 February 2018 in Bioorganic Chemistry
Verified
Journal Article
Closed access
KAKamelia M. Amin
Kamelia M. Amin
YSYasmin M. Syam
Yasmin M. Syam
MAManal Anwar
Manal Anwar
HAHamed I. Ali
Hamed I. Ali
TATamer M. Abdel-Ghani
Tamer M. Abdel-Ghani
ASAya M. Serry
Aya M. Serry

12 September 2018 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SESomaia Abd El-Karim
Somaia Abd El-Karim
MAManal Anwar
Manal Anwar
YSYasmin M. Syam
Yasmin M. Syam
MNManal A. Nael
Manal A. Nael
HAHanan F. Ali
Hanan F. Ali
MMMohamed A. Motaleb
Mohamed A. Motaleb

2 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
YSYasmin M. Syam
Yasmin M. Syam
MAManal Anwar
Manal Anwar
SESomaia Abd El-Karim
Somaia Abd El-Karim
KEKhaled Elokely
Khaled Elokely
SASameh H. Abdelwahed
Sameh H. Abdelwahed
Herein, 2,3-dioxo-1,2,3,4-tetrahydroquinoxaline was used as a bio-isosteric scaffold to the phthalazinone motif of the standard drug Olaparib to design and synthesize new derivatives of potential PARP-1 inhibitory activity using the 6-sulfonohydrazide analog 3 as the key intermediate. Although the new compounds represented the PARP-1 suppression impact of IC50 values in the nanomolar range, compounds 8a, 5 were the most promising suppressors, producing IC50 values of 2.31 and 3.05 nM compared to Olaparib with IC50 of 4.40 nM. Compounds 4, 10b, and 11b showed a mild decrease in the potency of the IC50 range of 6.35–8.73 nM. Furthermore, compounds 4, 5, 8a, 10b, and 11b were evaluated as in vitro antiproliferative agents against the mutant BRCA1 (MDA-MB-436, breast cancer) compared to Olaparib as a positive control. Compound 5 exhibited the most significant potency of IC50; 2.57 µM, whereas the IC50 value of Olaparib was 8.90 µM. In addition, the examined derivatives displayed a promising safety profile against the normal WI-38 cell line. Cell cycle, apoptosis, and autophagy analyses were carried out in the MDA-MB-436 cell line for compound 5, which exhibited cell growth arrest at the G2/M phase, in addition to induction of programmed apoptosis and an increase in the autophagic process. Molecular docking of the compounds 4, 5, 8a, 10b, and 11b into the active site of PARP-1 was carried out to determine their modes of interaction. In addition, an in silico ADMET study was performed. The results evidenced that compound 5 could serve as a new framework for discovering new potent anticancer agents targeting the PARP-1 enzyme.

1 April 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
KAKamelia M. Amin
Kamelia M. Amin
YSYasmin M. Syam
Yasmin M. Syam
MAManal M. Anwar
Manal M. Anwar
HAHamed I. Ali
Hamed I. Ali
TATamer M. Abdel-Ghani
Tamer M. Abdel-Ghani
ASAya M. Serry
Aya M. Serry